<DOC>
	<DOCNO>NCT01688037</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability two dos ( 50 100 mg ) NBI-98854 administered daily treatment Tardive Dyskinesia ( TD ) symptom .</brief_summary>
	<brief_title>NBI-98854 Treatment Tardive Dyskinesia Subjects With Schizophrenia Schizoaffective Disorder ( KINECT Study )</brief_title>
	<detailed_description>This Phase 2 , multicenter , randomize , double-blind , placebo-controlled , parallel group study evaluate efficacy , safety , tolerability two dos ( 50 100 mg ) NBI-98854 administer daily 2 week . The study also allow evaluation efficacy NBI-98854 50 mg daily 6 week safety tolerability NBI 98854 50 mg daily 12 week . The double-blind placebo-controlled treatment period study three arm : - NBI-98854 50 mg daily 6 week - NBI-98854 100 mg daily 2 week follow 50 mg daily remain 4 week - placebo At end 6-week placebo-controlled double-blind treatment period , subject continue study additional 6-week open-label period subject complete double-blind treatment period receive NBI-98854 50 mg daily . Two four week last dose study drug , follow-up assessment perform .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<criteria>Have clinical diagnosis schizophrenia schizoaffective disorder clinical diagnosis neurolepticinduced tardive dyskinesia least 3 month prior screen . Be receive stable dose antipsychotic medication minimum 30 day study start . Subjects use antipsychotic medication must stable psychiatric status . Have dos concurrent medication condition treat stable minimum 30 day study start expect remain stable study . Subjects childbearing potential must agree use hormonal two form nonhormonal birth control study . Female subject must pregnant . Be good general health expect complete clinical study design . Have body mass index ( BMI ) 18 38 kg/m2 ( inclusive ) . Have negative urine drug screen ( negative amphetamine , barbiturate , benzodiazepine , phencyclidine , cocaine , opiates , cannabinoids ) screen study start , except subject receive stable dose benzodiazepine . Have negative alcohol breath test screening study start . Have active clinically significant unstable medical condition within 1 month ( 30 day ) prior screen . Have history substance dependence substance ( drug ) alcohol abuse within 3 month study start ( nicotine caffeine dependence exclusionary ) . Have know history neuroleptic malignant syndrome . Have significant risk suicidal violent behavior . Receiving exclude concomitant medication reserpine , metoclopramide , stimulant , tetrabenazine . Receiving medication treatment tardive dyskinesia . Have positive human immunodeficiency virus antibody , ( HIVAb ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody result screen history positive result . Have receive investigational drug within 30 day screen plan use investigational drug ( NBI98854 ) study . Have allergy , hypersensitivity , intolerance tetrabenazine . Have previous exposure NBI98854 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>